<DOC>
	<DOCNO>NCT02831582</DOCNO>
	<brief_summary>This clinical trial study use omega-3 fatty acid supplementation prevent aromatase inhibitor-induced toxicity patient stage I-III breast cancer . An omega-3 supplementation may help relieve moderate severe bone pain improve joint symptom cause aromatase inhibitor-induced arthralgia .</brief_summary>
	<brief_title>Omega-3 Supplementation Prevention Aromatase Inhibitor-Induced Toxicity Patients With Stage I-III Breast Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine efficacy complementary therapy omega-3 fatty acid ( n-3 PUFA ) supplementation prevent aromatase inhibitor-induced arthralgia ( AIIAs ) . SECONDARY OBJECTIVES : I . To prospectively define population risk develop AIIAs identification validation genetic risk predictor develop single nucleotide polymorphism ( SNP ) /gene profile predictive treatment intervention response . OUTLINE : Patients randomize 1 2 group . Group I : Patients receive omega-3 fatty acid supplementation orally ( PO ) daily ( QD ) 6 month . Group II : Patients receive placebo PO QD 6 month . After completion study , patient follow periodically .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Arthralgia</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<criteria>Women diagnose breast cancer stag IIII initiate first line adjuvant aromatase inhibitor ( AI ) therapy FDAapproved AIs ( anastrazole , exemestane , letrozole ) Concurrent gonadotropinreleasing hormone ( GnRH ) agonist therapy allow ; concurrent breast related radiation therapy allow . Prior tamoxifen use allow Prior chemotherapy allow Ability understand willingness sign write informed consent document Metastatic malignancy kind Rheumatoid arthritis type autoimmune inflammatory joint disease AI use &gt; 21 day prior study enrollment Known bleeding disorder Current use warfarin anticoagulant Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Daily use n3 PUFA concentrate capsule supplement might interact n3 PUFA supplement &gt; 375 mg per day eicosapentaenoic acid ( EPA ) / docosahexaenoic acid ( DHA ) within six month study initiation Pregnant nursing woman Known sensitivity allergy fish fish oil Unable give inform consent</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Postmenopausal</keyword>
	<keyword>Stage IA</keyword>
	<keyword>Stage IB</keyword>
	<keyword>Stage IIA</keyword>
	<keyword>Stage IIB</keyword>
	<keyword>Stage IIIA</keyword>
	<keyword>Stage IIIB</keyword>
	<keyword>Stage IIIC</keyword>
</DOC>